PDCD1 and neoplasm: A phase I clinical trial found a relative increase in the abundance of enterococci in refractory metastatic melanoma following the use of PD-1 blockers and FMT, which led to intra-tumoral CD8+ T-cell infiltration and ultimately better tumor killing (64).